The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Active Surveillance for Prostate Cancer: Progress and Promise
Open accessAbstract
Widespread prostate-specific antigen (PSA) –based screening and aggressive treatment of prostate cancer have reduced mortality rates substantially, but both remain controversial in large part because of high rates of overdiagnosis and overtreatment of otherwise indolent tumors. Active surveillance—or close monitoring of PSA levels combined with periodic imaging and repeat biopsies—is gaining acceptance as an alternative initial management strategy for men with low-risk prostate cancer. In reported series, rates of progression to active treatment with intermediate-term follow-up have ranged from 14% to 41%, and likelihood of subsequent cure with surgery or radiation does not seem to be compromised by an initial trial of surveillance. Two related challenges to broader acceptance of surveillance are better characterization at time of diagnosis of the risk of progression (including likelihood that given tumor may have been undersampled by diagnostic biopsy) and validation of optimal end points once surveillance begins. Both are subjects of intense ongoing investigation, with emerging biomarkers and novel imaging tests expected to facilitate decision making substantially. Recent reports have suggested active surveillance can be a cost-effective approach and preserve quality of life, but these questions must be assessed more definitively in prospective cohorts. Ultimately, by minimizing the harms of overtreating low-risk prostate cancer, active surveillance may help settle the controversy surrounding prostate cancer screening and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074
Self-citationTime Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Self-citationMortality results from the Göteborg randomised population-based prostate-cancer screening trial
Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., & Lilja, H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70146-7 · Cited by 936
Cited by
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1- 13 C]Pyruvate
Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., Larson, P. E. Z., Harzstark, A. L., Ferrone, M., van Criekinge, M., Chang, J. W., Bok, R., Park, I., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006070 · Cited by 1,286
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Self-citationActive Surveillance for Prostate Cancer: A Systematic Review of the Literature
Dall’Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.072 · Cited by 602
Self-citationQuality-of-Life Effects of Prostate-Specific Antigen Screening
Heijnsdijk, E. A. M., Wever, E. M., Auvinen, A., Hugosson, J., Ciatto, S., Nelen, V., Kwiatkowski, M., Villers, A., Páez, A., Moss, S. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201637 · Cited by 427
Cooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
Self-citation
Metadata
- Authors
- Cooperberg, M. R., Carroll, P. R., & Klotz, L.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-09-20
- Volume
- 29
- Issue
- 27
- Pages
- 3669-3676
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2101436815
- Cited by
- 290
- References
- 59
- FWCI
- 31.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active Surveillance for Prostate Cancer: Progress and Promise. https://app.cochat.ai/papers/10.1200/jco.2011.34.9738
- The paper
- Cooperberg, M. R., Carroll, P. R., & Klotz, L. (2011). Active Surveillance for Prostate Cancer: Progress and Promise. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.34.9738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.